^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Ontruzant (trastuzumab-dttb) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
11/15/2017
Excerpt:
Ontruzant is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):...in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable....in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease….in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin….in combination with neoadjuvant chemotherapy followed by adjuvant Ontruzant therapy, for locally advanced (including inflammatory) disease or tumours >2 cm in diameter....Ontruzant should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.
Secondary therapy:
paclitaxel; docetaxel; carboplatin + docetaxel; Chemotherapy
Source:
Published date:
11/15/2017
Excerpt:
Ontruzant is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):...as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease….Ontruzant should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.
